The association between endothelial dysfunction and late onset hypogonadism (LOH) in patients with vasculogenic erectile dysfunction (ED) is not yet well settled. Our objective was to assess the association between LOH and endothelial dysfunction in patients with vasculogenic ED. Throughout 2014-2015 a total of 90 men were enrolled in this cross-sectional observational study. Of them 60 patients with a clinical diagnosis of ED were further subdivided into two equal groups: patients with vasculogenic ED and LOH (A); patients with vasculogenic ED and euogonadal (B). Thirty age-matched men with no ED or hypogonadism were enrolled as control group (C). All patients were subjected to detailed medical and sexual history, total testosterone (TT), calculated free (FT) and bioavailable testosterone (BT), flow cytometric evaluation for endothelial progenitor cells (EPCs) (CD45negative/CD34positive/ CD144positive) and endothelial microparticles (EMPs) (CD45negative/CD144positive/annexin V positive). The mean age AE SD of the three groups A, B and C were 51.3 AE 11.1, 53.6 AE 10.6 and 48.3 AE 5 years, respectively, with insignificant age differences (p = 0.089). The diagnostic criteria of LOH were adapted according to European male aging study, 2010. The means of TT(ng/mL) were 2.32 AE 0.21, 6.43 AE 0.36 and 5.37 AE 0.30 in groups A, B and C, respectively. There were highly significant differences between group A and groups B and C (p < 0.001 for each). The means of EPCs were 0.43 AE 0.070, 0.22 AE 0.05 and 0.032 AE 0.013 in groups A, B and C, respectively. The means of EMPs were 0.15 AE 0.029, 0.056 AE .013 and 0.014 AE 0.002 in groups A, B and C, respectively. There were significant differences between group C and groups A and B (p < 0.05 for each). This study clearly demonstrated that there is a significant association between LOH and the higher expression of EPCs and EMPs in patients with vasculogenic ED.
INTRODUCTION
Up to 80% of erectile dysfunction (ED) cases are because of organic causes and vascular disease is the most common pathophysiological factor. The pivotal role in the occurrence of vasculogenic ED is loss of the functional integrity of the endothelium and subsequent endothelial dysfunction. ED, aging, hypogonadism and endothelial dysfunction are closely related to each other (Chiurlia et al., 2005) . Testosterone (T) deficiency is the most common hormonal cause of ED and has been recently considered as a global health issue which is associated with cardiovascular morbidity and mortality Corona et al., 2011; Grossmann & Wu, 2014) . Furthermore, Corona et al., reported that only the association of several symptoms and signs could significantly raise the clinical suspicion of low T (Corona et al., 2012) .
In addition, T is a critical factor to the health of the vascular beds, which acts through androgen receptor/vascular endothelial growth factor-mediated mechanism (AR/VEGF) and promoting angiogenesis that ultimately stimulating endothelial cell proliferation. Furthermore, T deprivation may have a direct effect on endothelial function and the differentiation, maturation, migration and homing of circulating endothelial progenitor cells (EPCs) through the availability of nitric oxide (NO) which is a key marker of endothelial function (Kelly & Jones, 2013) .
As endothelial microparticles (EMPs) released from the injured vessels and EPCs involved in vascular regeneration, the evaluation of EPCs and EMPs represents a reliable method to screen the endothelial alterations in patients with vasculogenic ED (Foresta et al., 2010; Sabatier et al., 2011) . Reduced T concentrations have been linked to the impairment of the vasculogenic reparative process mediated by EPCs and consequently affecting re-endothelialization (Foresta et al., 2008) .
La Vignera et al. have demonstrated an increase in serum concentrations of late phenotype of ECPs (CD4S negative 'neg' /CD34 positive 'pos' /CD144 'pos' ) in patients with arterial ED (La Vignera et al., 2011a , 2012a . Furthermore, Condorelli et al. reported that, the use of these markers is valuable as these changes usually ahead the structural alterations resulting from vascular damage (Condorelli et al., 2012 (Condorelli et al., , 2013a . Furthermore, other study had demonstrated that patients with hypogonadism had a low number of EPCs, and their number had increased significantly after testosterone replacement therapy (Foresta et al., 2008) .
Although EPCs and EMPs were previously reported of value in diagnosis and prognosis of ED with different risk factors ((Foresta et al., 2008; La Vignera et al., 2011a , 2012a Condorelli et al., 2012) , however, inconsistency of the results and lack of clear homogeneity among studies prompted us to investigate the association between EPCs & EMPs and late onset hypogonadism (LOH) in patients with vasculogenic ED.
MATERIAL AND METHODS

Research design
This is a cross-sectional observational office-based study. From January 2014 to June 2015 a total of 90 men were enrolled in this study. Of them 60 patients with a clinical diagnosis of ED who had attended to urology clinic at Suez Canal University and who had agreed to participate were enrolled in this study. Patients were subdivided into two equal groups (A-B); patients with vasculogenic ED and LOH (A); patients with vasculogenic ED and normal testosterone level (B). Thirty age-matched men who had attended to urology clinic for reasons other than ED and who had no hypogonadism were enrolled as a negative control group (C). All patients were subjected to: detailed medical and sexual history including International Index of Erectile Function (IIEF). The erectile function domain consists of questions 1 to 5 and question 15 for assessing the global erectile function Scoring of the IIEF domain of erectile function allowed classification of each patient as having no (26-30), mild (17-25), moderate (11-16) or severe (0-10) ED (Rosen et al., 1997) . Complete physical examination, laboratory assessment including, total testosterone (TT), estradiol, Sex hormone binding globulin (SHBG), albumin, calculated free (FT) and bioavailable testosterone (BT). Flow cytometry was used to evaluate EPCs (CD45neg/CD34pos/CD144pos) and EMPs (CD45neg/CD144-pos/annexin Vpos) for all patients. Patients in group A and B underwent penile Color Doppler Ultrasound (CDU).
Inclusion criteria
Hypogonadal ED group-A: Adult males aged >30 years, TT˂320 ng/dL and/or FT ˂6.4 ng/dL, BT <110 ng/dL, penile CDU' revealed arteriogenic ED, venogenic ED or mixed arteriogenic and venogenic ED. Euogonadal ED group-B: Adult males aged >30 years, TT ≥320 ng/dL, FT ≥6.4 ng/dL and BT ≥110 ng/ dL, penile CDU revealed arteriogenic ED, venogenic ED, or mixed arteriogenic and venogenic ED. Eugonadal with no ED group-C: Adult males aged >30 years, TT ≥320 ng/dL, FT ≥ 6.4 ng/dL and BT ≥110 ng/dL, they have no ED complaint.
The diagnostic criteria of LOH were adapted according to European male aging study (presence of at least three sexual symptoms associated with TT ˂3.2 ng/mL (˂320 ng/dL) and FT ˂6.4 ng/dL, BT <110 ng/dL) (Wu et al., 2010) . A serum sample determination was obtained between 8 and 11am on three occasions.
Body mass index (BMI kg ⁄m2) was rated as follows: normal (<25), overweight (25-29.9 ) and obese (≥30) (WHO 1995 
Doppler ultrasound examination of the penis
Color Doppler ultrasound was carried out using a linear probe (SIEMENS, GM-6600A2E00) with 7.5 MHz frequency. After intracavernosal injection (ICI) of 10 lg prostaglandin E1 (Caverject, Pfizer, New York, NY, USA) as a titration dose, if the patient has not responded well we have escalated the dose up to 20 lg in 1 week duration. Patients were allowed 5 min of manual self-stimulation then CDU technique was performed as previously described. Arteriogenic ED was diagnosed when PSV is lower than 35 cm/sec, venogenic ED was diagnosed when EDV is higher than 5 cm/sec and RI is lower than 0.9. Mixed arteriogenic and venogenic ED was diagnosed when PSV is lower than 35 cm/sec. and concomitant EDV is higher than 5 cm/sec (Donatucci & Lue, 1992) .
Hormonal evaluation
Total T and E2 were assessed using electrochemiluminescence immunoassays 'ECLIA' according to the manufacturer's instructions (Roche/Hitachi COBAS e 411 immunoassay analyzers; Roche Diagnostics Corporation, Mannheim, Germany). SHBG was measured using ELISA technique (DRG kit GmbH, Germany) and was read by (Infinite â F50/Robotic ELISA plate readers). The normal range was: 20-60 nmol/L, FT and BT were calculated by the equation which was developed by ISSAM, (www.issam.ch).
Flow cytometric evaluation for EPCs and EMPs
Endothelial progenitor cells and EMPs evaluation was measured from blood after incubation in erythrocyte lysing solution for 1 min. The suspension then washed twice with phosphatebuffered solution (PBS) and centrifuged, and the pellet was rapidly incubated in PBS containing the appropriate monoclonal antibodies at room temperature for 20 min. After incubation, the pellet was washed, then acquired for analysis by fluorescence-activated cell sorting (FACS) calibur flow cytometry (BD Biosciences, San Jose, CA, USA). (Masouleh et al., 2010; Condorelli et al., 2012) . After incubation, the pellet was washed, then acquired for analysis.
Endothelial progenitor cells measurement; (PERCP) conjugated anti-human CD45 (BD), fluorescein isothiocyanate (PE)-conjugated anti-human CD34 (BD), and r-phycoerythrin (FITC)-conjugated anti-human CD144 (BD) were used for EPCs flow cytometry detection. Each sample was analyzed by flow cytometry (FACS Calibur BD Biosciences). EPCs were reported as percentage of total events (Masouleh et al., 2010; Condorelli et al., 2012) .
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Percp anti-human CD45 (BD Immunosystem), PE conjugated anti-human CD144 (BD Immunosystem) and FITC-conjugated Annexin V (BD Immunosystem) were used for EMPs detection. To exclude MPs originating from leukocytes, we considered only events within the CD45 negative gate. CD144 positive events expressing Annexin V were defined as EMPs. They were reported as percentage of total events. Appropriate isotype controls were used for each staining procedure as negative controls to set the appropriate regions (Van Ierssel et al., 2010; Condorelli et al., 2012) .
Flow cytometric analysis was conducted for 600 sec or 100,000 events, whichever occurred first, this process depends on the cellular content, if a sample can provide 100,000 event we stop acquisition if not we should wait for 600 sec before stopping it. The same operator was blinded with respect to the sample origin (controls or patients). The institutional research and ethical committee (Institution Review Board) had reviewed and approved the study. Each patient had provided an informed consent.
Statistical analysis
Data collected from the study individuals were analyzed using the Statistical Package for the Social Sciences (SPSS© ver.21.0, Inc., Chicago, IL, USA) software program. The test of normality (Kolmogorov-Smirnov test) was performed for each comparison of means. Significance test used for qualitative variables was Chi-square test; unpaired two-sided Student's t test was used to compare means of two variables and ANOVA was used to compare means of more than two variables of normally distributed parameters. While Mann-Whitney U-test was used to compare means of two variables and Kruskal-Wallis test was used to compare means of more than two variables of not normally distributed parameters in all other cases. A p-value < 0.05 was considered statistically significant.
RESULTS
Sociodemographics and characteristics of the study populations
The mean age AE SD of the three groups A, B and C were 51.3 AE 11.1, 53.6 AE 10.6 and 48.3 AE 5 years, respectively, with insignificant age differences (p = 0.089). In group A, B and C 66.7%, 56.7% and 10.0% had more than one vascular risk factor, respectively (p = 0.001) ( Table 1) . Most of patients with moderate and severe ED were current or ex-smoker (p = 0.036). 93.4% of patients in group A were overweight or obese (p = 0.001).
Hormonal and CDU evaluation
The means of TT(ng/dL) were 232 AE 21, 643 AE 36 and 537 AE 30 in groups A, B and C, respectively. The means of FT (ng/dL) were 2.73 AE 0.16, 9.35 AE 0.59, and 11.0 AE 0.65 in groups A, B and C, respectively. The means of BT(ng/dL) were 64.3 AE 3.70, 219.6 AE 13.9, and 258.3 AE 15.5 in groups A, B and C, respectively. There were highly significant differences between group A and the other groups B and C regarding (TT, FT and BT) (p = 0.001 for each) ( Table 2) . Patients in group A had lower mean and median PSV and RI than group B (p < 0.05 for each) (Table 3 ). Of patients in group A, 53.3% had severe impairment of Doppler parameters (PSV<25 m/sec, EDV >5 cm/sec, RI <0.9) in comparison to 23.3% in patients in group B.
Endothelial markers evaluation
The means of EPCs were 0.43 AE 0.070, 0.22 AE 0.05 and 0.032 AE 0.013 in groups A, B and C, respectively. There were significant differences between group C and the other two groups A and B (p < 0.05 for each) (Table 4 and Fig. 1A,B) . The means of EMPs were 0.15 AE 0.029, 0.056 AE .013 and 0.014 AE 0.002 in groups A, B and C, respectively. There were significant differences between group C and groups A and B (p < 0.05 for each) (Table 4 and Fig. 1A,C) . 
DISCUSSION
In this study, we aimed to evaluate the association between LOH and endothelial dysfunction in patients with vasculogenic ED. We determined significant increase in means of EPCs and EMPs among patients with both ED and LOH in comparison to patients in the other two groups. Sixty percent of the ED patients and 33.3% of the control group were current or ex-smoker (p = 0.004). Smoking is a risk factor for development of ED; endothelial dysfunction and subsequent atherosclerosis is the final end result of smoking because of its nicotinic component that has a direct effect on endothelial cells. In the Massachusetts Male Aging Study (MMAS), the risk of developing moderate or total ED was significantly higher in men who were smokers at baseline . As a long-term effect of smoking, previous studies have displayed increased levels of EMPs which reflect impairment of endothelial function and increase vascular injury and repair as systemic effects Mobarrez et al., 2014) .
Total testosterone can be used in assessment of hypogonadism, especially in screenings and wide-scale studies. However, free and bioavailable testosterone levels may provide a better estimation of testicular endocrine function. In this study, the levels of TT, FT and BT were significantly lower in the hypogonadal group in comparison to the other two groups.
The mean of TT level in the hypogonadal group was about one-third of eugonadal group, 232 AE 21 vs. 643 AE 36 (p < 0.004), this result was correlated with CDU results which showed that: 90% of hypogonadal patients had PSV<35 m/sec and 70% had EDV >5 as compared with 66.7% had PSV <35 m/ sec and 40% had EDV >5 in eugonadal group. Several previous studies had demonstrated that the incidence of ED increased with concurrent decline in androgen levels (Foresta et al., 2000) . The results of the Baltimore Longitudinal Study documented that TT levels were decreased approximately1% per year in men from their 30s (Harman et al., 2001) . Another study reported a significant decrease in TT level throughout a 4-year follow-up especially in patients with severe ED (El-Sakka & Hassoba, 2006) .
In this study the investigated VRF were diabetes, hypertension, dyslipidemia, coronary artery diseases, obesity and smoking. Forty patients had VRF, of them 30 patients (75%) had type 2 diabetes either alone or in combination with other medical comorbidities followed by hypertension in 9/40 (22.5%). Of the 40 patients who had VRF, only 3 patients (7.5%) were in the control group, whereas 37 patients (92.5%) had either ED alone or ED and hypogonadism. There were significant differences between control group and the other two groups regarding VRF; however, there were no significant differences in VRF between patients in hypogonadal and eugonadal groups which attenuate their effects in the multivariate analysis. BMI was significantly higher in hypogonadal patients in comparison to eugonadal and control groups (p = 0.001). In consistent with these results, previous studies had shown that, age and BMI were significantly higher in patients with low T level than in patients with normal T level (Corrales et al., 2004) . Recent studies had also shown that, about one-third of men with DM presented with LOH. Furthermore, ED was associated with lower urinary tract symptoms (El-Sakka, 2005) and was the first sign of DM that diagnosed later (Ogbera et al., 2011; Kamenov, 2015) .
Pelliccione et al. reported that serum from men with ED and VRFs negatively modulated the number of ex vivo expanded circulating angiogenic cells (CACs) derived from circulating mononuclear cells of healthy men (Pelliccione et al., 2012 ). More ED, erectile dysfunction; LOH, late onset hypogonadism; PSV, peak systolic velocity; EDV, end-diastolic velocity; R, resistance index. *Calculating using MannWhitney U, (p < 0.05 is considered significant). recently D'Andrea et al., reported that serum from patients with ED and VRFs triggered an oxidative stress-dependent mitochondrial apoptotic pathway in ex vivo expanded CACs of healthy men (D'Andrea et al., 2016) . The results of penile CDU showed that 53.3% of hypogonadal patients had severe impairment in Doppler parameters (PSV<25 m/sec, EDV >5 cm/sec, RI <0.9) in comparison to 23.3% in eugonadal group. The impairment of CDU parameters may reflect the degree of diminution in arterial blood flow and attenuation of veno-occlusive mechanism in hypogonadal patients and highlight the effects of androgen in vascular wall, penile structural changes and tunica albuginea integrity. Although, arteriogenic and venogenic ED are different conditions with different etiologies and variable consequences; in this study, most of the ED patients had either PSV<35 m/sec only or both PSV<35 m/sec and EDV >5. As such, the result of this study reflected the association between hypogonadism and endothelial dysfunction, in patients with arteriogenic or mixed ED.
In this study, we found that patients with vasculogenic ED and LOH had higher level of circulating EPCs, than ED alone or control patients. These findings may reflect the exaggerated penile vascular damage in hypogonadal patients with ED than patients in the other two groups. The repairing process is initiated by stimulation of bone marrow to produce EPCs because of endothelial damage. After arrival to the site of injury EPCs necessitate cell to cell adhesion to undergo differentiation, activation, maturation and homing. Currently, EPCs and EMPs are claimed as a biomarker for several vascular impairment conditions such as CVD and atherosclerosis. (Dotsenko, 2010) (Table 5) .
On the contrary, other study had investigated the effect of TRT on the number of circulating EPCs in hypogonadal patients, the results showed that post-TRT, T levels and EPC numbers had increased significantly compared with the baseline level in which T level had no significant association with the number of circulating EPCs (Liao et al., 2013) (Table 5) . Using of CD131, VEGFR2 in the CD34 triple-positive cells by the dual expression may signify a true limitation of this study in which the number of EPCs calculated by this dual marker will be much less than the actual number.
EPCs had been used for the diagnosis of ED associated endothelial dysfunction. Increase in serum concentrations of late phenotype of EPCs (CD4S neg /CD34 pos /CD144 pos ) in patients with arterial ED was recently reported. Upregulation of EPCs is probably because of a more advanced phase of cell differentiation compared to early phenotypes (La Vignera et al., 2012a). Condorelli et al. stated that, the clinical use of these markers is valuable and explained that by their changes which precede the structural alterations resulting from vascular damage (Condorelli et al., 2012 (Condorelli et al., , 2013a (Table 5) .
EPCs may be an independent risk factor of ED which could explain the reduction in EPCs number in patients with ED without cardiovascular risk factors. Furthermore, EPCs may be beneficial to restore erectile function through the regeneration and improvement of the endothelial function of the cavernosal arteries. This finding may enhance the clinical utilization of EPCs in the future (Baurnhakel et al., 2006) . However, the correlation between EPCs and ED was only found with CD133 pos cells and not with CD34 pos or KDR pos cells (Fadini et al., 2007) (Table 5 ). This argument points out the need to standardize the functionality of EPCs at different stages and to optimize the method for EPCs measurements.
On the other hand, several previous studies had demonstrated that the serum concentrations of EPCs were significantly higher in the presence of classical cardiovascular risk factors such as metabolic syndrome (MetS); hypogonadism; atherosclerosis and coronary artery disease (CAD) which showed diminution after pharmacological intervention with androgens, phosphodiesterase type 5 inhibitors (PDE5I) and physical activity (La Vignera et al., 2011a ,b, 2012a Condorelli et al., 2012 Condorelli et al., , 2013b (Table 5) .
This study clearly demonstrated that there was significant upregulation of EPCs (CD45 neg CD34 pos CD144 pos ) and EMPs (CD45 neg /CD144 pos /Annexin v pos ) in patients with vasculogenic ED and LOH in comparison to the other two groups with ED alone or control group. The phenotype that was used in this study has examined a dynamic phase of the endothelial response particularly a late differentiative phase of EPCs. This phenotype has been previously shown to be a potentially usable in clinical practice and its number could emerge as a novel cellular biomarker in diagnosis and prognosis of endothelial dysfunction associated ED (La Vignera et al., 2011a; Condorelli et al., 2013b) .
The discrepancy among previous studies may be explained by using different phenotypes which express different functional state of endothelial repair at different time points. Ultimately, in EPC S , endothelial progenitor cells; EMPs, endothelial microparticles; ED, erectile dysfunction; LOH, late onset hypogonadism; TRT, testosterone replacement therapy; CAD, coronary artery disease; PDE5I, phosphodiesterase type 5 inhibitors; MetS, metabolic syndrome; VEGF, vascular endothelial growth factor; CD, cluster of differentiation; pos, positive; neg, negative.
532 Andrology, 2017, 5, 527-534 the future these markers may be applied as indicators for the endothelial dysfunction in patients with hypogonadism-associated vasculogenic ED. The main limitations of this study were, the number of study population was relatively small and the functionality of EPCs at different stages of production, migration and homing were not obtained. As patients in the control group had no ED complaint we claimed that they had normal vascular pattern and no Doppler assessments for their vascular status were performed. Further studies are warranted to address the effect of testosterone deficiency on factors that affect different stages of EPCs functionality.
CONCLUSION
This study clearly demonstrated that there is a significant association between LOH and the higher expression of EPCs and EMPs in patients with vasculogenic ED. This finding may reflect the importance of addressing EPCs and EMPs in investigating the association between testosterone level and endothelial dysfunction in patients with vasculogenic ED.
